TSHA-102 has reached FDA written alignment on inclusion of safety data from the ASPIRE trial to support a broad label in patients aged 2 years and older with Rett syndrome, streamlining the path toward BLA submission. With dosing completion expected in Q2 2026 across pivotal trials and an estimated 15,000 to 20,000 patients affected by Rett syndrome across the U.S., EU and U.K., Taysha is positioned to redefine the treatment paradigm for this devastating disease with high unmet need.
Cyborg Score Rationale
REVEAL Part A demonstrated a 100% response rate in developmental milestones with TSHA-102 being well tolerated, and the compound received FDA breakthrough therapy designation emphasizing its potential to address significant unmet needs in Rett syndrome. Clear regulatory pathway and pipeline focus on high-value rare CNS diseases provide execution visibility.
Top Insights
First patient dosed in REVEAL pivotal trial in Q4 2025 with enrollment advancing across multiple sites
Pipeline includes eight additional programs spanning giant axonal neuropathy, CLN7 disease, CLN1 disease, SLC13A5 deficiency, tauopathies, Angelman syndrome, fragile X syndrome, and GM2 gangliosidosis
Part A of REVEAL demonstrated 100% response rate in developmental milestones
Company hired three new employees in early February 2026, indicating continued expansion
Named Competitors
AAV Gene Therapies for Rare CNS Diseases — AAV-based gene therapy platform targeting inherited retinal disease and neurological disorders
AAV-Based Gene Therapy for Lysosomal Storage Diseases — Developing AAV gene therapies for CNS lysosomal storage disorders
Gene Therapy for Monogenic CNS Diseases — Developing gene therapies targeting neurodegenerative and CNS genetic disorders
Recent Developments
(February 2026) Granted 349,000 RSUs to three new employees under 2023 Inducement Plan
(January 2026) Dosed first patient in REVEAL pivotal trial for TSHA-102 with enrollment advancing across multiple sites
(January 2026) Reached FDA written alignment to include ASPIRE trial safety data in BLA submission supporting broad label for patients aged 2+ years
Open the full interactive Taysha Gene Therapies, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.